Autifony Therapeutics's £10 million boost
11 April 2012
Some of the UK's six million tinnitus sufferers could face relief after a company developing potential treatments received a £10 million funding boost.
Half of the cash to Autifony Therapeutics came from Imperial Innovations, which funds projects developed by university research faculties, with the rest coming from pharma firms SV Life Sciences and GlaxoSmithKline.
Autifony will speed up its pre-clinical development programme on the ear's ion channels, which convert mechanical vibrations into brain signals and affect tinnitus.
